Orion Oyj (LON:0M2O)

Market Cap	8.20B +29.0%
Revenue (ttm)	1.65B +22.5%
Net Income	436.45M +51.7%
EPS	3.10 +51.5%
Shares Out	n/a
PE Ratio	18.79
Forward PE	18.07
Dividend	1.49 (2.24%)
Ex-Dividend Date	Mar 25, 2026

Volume	19,918
Average Volume	96,122
Open	67.65
Previous Close	66.47
Day's Range	67.00 - 67.75
52-Week Range	46.66 - 75.40
Beta	0.36
RSI	44.02
Earnings Date	Apr 23, 2026

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. It offers pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Quetiapine products for antipsychoti...

• Industry: Pharmaceutical Preparations
• Founded: 1917
• Employees: 4,029
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0M2O

Financial Performance

In 2025, Orion Oyj's revenue was 1.89 billion, an increase of 22.50% compared to the previous year's 1.54 billion. Earnings were 500.30 million, an increase of 51.65%.

Financial numbers in EUR